|Videos|August 29, 2018
Dr. Ostertag on Emerging CAR T Product for Myeloma
Author(s)Eric M. Ostertag, MD, PhD
Eric M. Ostertag, MD, PhD, chief executive officer, Poseida Therapeutics, Inc., discusses an emerging CAR T stem cell memory product for patients with relapsed/refractory multiple myeloma.
Advertisement
Eric M. Ostertag, MD, PhD, chief executive officer, Poseida Therapeutics, Inc., discusses an emerging CAR T stem cell memory product for patients with relapsed/refractory multiple myeloma.
Phase I data for the CAR T stem cell memory product P-BCMA-101 was presented at the 2018 AACR Annual Meeting. A major difference between this product and other CAR T cells is that it was not created using a virus; instead, developers used a technology called DNA transposon. An advantage of this manufacturing technique, Ostertag says, is that it allows researchers to essentially have unlimited cargo capacity. A centyrin is then added to the product instead of a commonly used antibody. Researchers also added a gene that allows for a positive selection. Ostertag says there are data that suggest this translates into a better therapeutic index because it not only kills the tumor, but it also releases cytokines.
The ongoing phase I trial has shown efficacy in 3 patients, including one partial response lasting more than 10 weeks at time of data cutoff.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Advertisement
Related Articles
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025
- CGTLive®’s Weekly Rewind – September 12, 2025
September 12th 2025
- Around the Helix: Cell and Gene Therapy Company Updates – September 10, 2025
September 10th 2025
- CGTLive®’s Weekly Rewind – September 5, 2025
September 5th 2025
Advertisement
Advertisement